The 27th European Congress of Psychiatry, organised by the largest international association of psychiatrists in Europe, will take place between 6 and 9 April 2019 in Warsaw.
Psychiatry is facing a generative transition involving the organisation of mental health services, traditional approaches to diagnosis, models of care, and research paradigms.
Drugs: North West is a newly-formed network of researchers from across North West England. The network was established to foster multi-disciplinary collaborations between researchers across the region and to provide a platform to showcase the innovative work of its members.
The National Leadership Conference is the annual gathering for families and stakeholders brought together by the Addiction Policy Forum.
This event highlights innovative solutions to addressing addiction, connects those working on the ground with skills and new tools.
The 1st Asia Regional Meeting of the International Society for the Study of Drug Policy will be held at the University of Hong Kong from 14 -15 October 2019.
Reinforcing Behaviour Change in Addiction Treatment' will present findings from the National Institute for Health Research (NIHR) Programme grant which sought to develop an evidence base for contingency management in addiction services in the UK.
After alcohol, cannabis is the second most common intoxicant in the Nordics.
The European Federation of Therapeutic Communities (EFTC) Conference aims to provide to member organizations and colleagues from all disciplines of drug treatment the opportunity to present, question, clarify and communicate the results, and evaluation of the processes of addiction recovery achieved in therapeutic communities.
The Cross Party Group on Alcohol and Drugs will host their Annual General Meeting in the Scottish Parliament on the 26th of February 2019.
Xchange is an online registry of evidence-based prevention programmes. In its first phase, the registry will make available manualised interventions that European evaluation studies show have beneficial outcomes relating to substance use. For programmes of US origin, the registry also provides the evidence level of the evaluation studies conducted there (Blueprint ratings).